Drug intelligence / Profile preview

ONYCR2

Development stage: Phase 2
Lead developer: Onyvax
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

ONYCR2 is an allogeneic adenocarcinoma cell-based vaccine developed by Onyvax. It is being investigated in a Phase I/II clinical trial for the treatment of locally advanced or metastatic colorectal cancer. As a cell-based vaccine, its mechanism involves stimulating the body's immune system to recognize and kill colorectal tumor cells.

Beyond the preview

Go deeper on ONYCR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONYCR2.

Explore the full profile